Humira (adalimumab) is now indicated to treat children age 6 years and older with moderately to severely active Crohn’s disease who have had an inadequate response to treatment with corticosteroids or immunomodulators.
After conducting a population-based, nationwide cohort study, researchers reported a relationship between inflammatory bowel disease (IBD), especially Crohn’s disease (CD), and cervical neoplasia.
Advances in knowledge surrounding gastrointestinal conditions have paved the way for improvements in Crohn’s disease (CD) treatment. To aid clinicians in managing patients with CD, the American Gastroenterological Association (AGA) created a clinical decision tool to effectively guide gastroenterologists throughout their decision-making process.
Researchers at Beth Israel Deaconess Medical Center (BIDMC) reported that proactive monitoring of dose adjustments of infliximab (IFX), one of the 4 anti-TNF-alpha proteins used to treat inflammatory diseases like Crohn’s disease (CD), ulcerative colitis (UC), and inflammatory bowel disease (IBD), could prolong the effectiveness of treatment.
Experts have discovered a possible correlation between treatment with isotretinoin and decreased risk of inflammatory bowel disease, according to a study published in the Journal of American Medical Association Dermatology.
A research team with members at the University of California, Los Angeles (UCLA) has discovered genetic factors involved in a severe form of inflammatory bowel disease (IBS), pediatric ulcerative colitis.